In this international , multicenter , randomized , double-blind , active-controlled , crossover , confirmatory phase III trial ( adept ( ) 2 ) in patients with hemophilia A or B and inhibitors , bleeds were randomized 3 : 2 to treatment with vatreptacog alfa ( one to three doses at 80 g kg ( -1 ) ) or rFVIIa ( one to three doses at 90 g kg ( -1 ) ) .